Related Experiment Video
Updated: Jan 18, 2026

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
Published on: March 28, 2018
[New therapeutic approaches for the treatment of primary biliary cholangitis]
Corentin Brice1, Alexandre Louvet1
1Service des maladies de l'appareil digestif. Centre de compétence Maladies rares « Maladies inflammatoires des voies biliaires et hépatites autoimmunes », Hôpital Huriez, Lille, France.
Abstract:
Primary biliary cholangitis (PBC) is a rare disease for which management long consisted of a single treatment: ursodeoxycholic acid. In 2015-2016, this disease regained interest with the first studies on obeticholic acid (FXR agonist) and then on bezafibrate (PPAR agonist). Subsequently, over the past five years, significant progress has been made in the management of PBC. Major studies have helped better predict disease progression and its response to treatment through the development of prognostic tools. Additionally, the therapeutic arsenal has expanded with the arrival of selective PPAR agonists.
Related Concept Videos
Chronic Pancreatitis II: Collaborative Care
Assessment:
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Acute Pancreatitis II: Clinical Manifestations and Management
Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Direct-Acting Cholinergic Agonists: Therapeutic Uses
